TAAR1 Agonist Ulotaront Improves Glycemic Control, Reduces Body Weight and Modulates Neurocircuits Governing Energy Balance and Feeding in Rodents

被引：0

作者：

Dedic, Nina ^{[1
]}

Hajos-Korcsok, Eva ^{[1
]}

Jones, Phil G. ^{[1
]}

Synan, Colleen ^{[1
]}

Wu, Serena ^{[1
]}

Anacker, Christoph ^{[1
]}

Vickers, Steven P. ^{[1
]}

Hecksher-Sorensen, Jacob ^{[1
]}

Milanovic, Snezana ^{[1
]}

Bristow, Linda J. ^{[1
]}

Koblan, Kenneth S. ^{[1
]}

机构：

[1] Sunovion Pharmaceut Inc, Marlborough, MA USA

来源：

NEUROPSYCHOPHARMACOLOGY | 2022年 / 47卷 / SUPPL 1期

关键词：

TAAR1; Schizophrenia- Novel Treatment; Antipsychotic-Induced Metabolic Dysfunction; Metabolic Side-Effects;

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

P180

引用

页码：166 / 166

页数：1

共 9 条

[1] TAAR1 Agonist Ulotaront Improves Glycemic Control, Reduces Body Weight and Modulates Neurocircuits Governing Energy Balance and Feeding in Rodents
Dedic, Nina
Hajos-Korcsok, Eva
Jones, Phil G.
Synan, Colleen
Wu, Serena
Anacker, Christoph
Vickers, Steven P.
Hecksher-Sorensen, Jacob
Milanovic, Snezana
Bristow, Linda J.
Koblan, Kenneth S.
NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 166 - 166
[2] TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Dedic, Nina
Wang, Lien
Hajos-Korcsok, Eva
Hecksher-Sorensen, Jacob
Roostalu, Urmas
Vickers, Steven P.
Wu, Serena
Anacker, Christoph
Synan, Colleen
Jones, Philip G.
Milanovic, Snezana
Hopkins, Seth C.
Bristow, Linda J.
Koblan, Kenneth S.
MOLECULAR METABOLISM, 2023, 80
[3] TAAR1 Agonist Ulotaront Improves Glycemic Control and Reduces Body Weight in Rodent Models of Diabetes, Obesity, and Iatrogenic Weight Gain
Dedic, Nina
Jones, Philip G.
Hajos-Korcsok, Eva
Synan, Colleen
Wu, Serena
Anacker, Christoph
Vickers, Steve P.
Hecksher-Sorensen, Jacob
Zeni, Courtney
Milanovic, Snezana
Hopkins, Seth C.
Bristow, Linda J.
Koblan, Kenneth S.
CNS SPECTRUMS, 2023, 28 (02) : 259 - 259
[4] A novel selective PPAR-α agonist, CP900691, improves plasma lipids, lipoproteins, glycemic control and reduces body weight in diabetic monkeys
Flynn, Mickey
Shadoan, Melanie K.
Kavanagh, Kylie
Zhang, Li
Auerbach, Bruce J.
Harwood, H. J.
Wagner, Janice D.
DIABETES, 2007, 56 : A138 - A138
[5] The New Dual Glucagon-GLP-1 Agonist ZP2929 Improves Glycemic Control and Reduces Body Weight in Murine Models of Obesity and Type 2 Diabetes
Daugaard, Jens R.
Meier, Eddi
Riber, Ditte
Baek, Camilla A. E.
Larsen, Kjeld S.
Kampen, Gita
DIABETES, 2010, 59 : A430 - A430
[6] Novel Oral Small Molecule GLP1 Agonist Reduces Body Weight and Improves Glucose Control in DIO Mice
Medley, Kyle
Bearss, David
Lin, Chenyu
Vankayalapati, Hariprasad
OBESITY, 2024, 32 : 166 - 167
[7] Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
Chen, Yanyun
Mezo, Adam
Coskun, Tamer
Song, Min
Roell, William C.
Bokvist, Krister B.
Moyers, Julie S.
Thomas, Melissa K.
Valenzuela, Francisco
Qu, Hongchang
DIABETES, 2021, 70
[8] The Novel Long Acting GLP-1/Glucagon Dual Agonist HM12525A Reduces Body Weight and Improves Glycermic Control in Rodent Models
Jung, Sung Yeob
Kim, Jin Sun
Choi, In Young
Lee, Kyu Hang
Lee, Young-Mi
Kim, Young Hoon
Kang, Jahoon
Kwon, Se Chang
DIABETES, 2013, 62 : A268 - A268
[9] The new dual glucagon-GLP-1 agonist ZP2929 improves glycaemic control and reduces body weight in murine models of obesity and insulin resistance
Daugaard, J. R.
Riber, D.
Larsen, K. S.
Maier, E.
Baek, C. A. E.
Kampen, G.
DIABETOLOGIA, 2010, 53

← 1 →